Elanco Animal Health Incorporated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax
Elanco Animal Health Incorporated (ELAN) reported Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax of $4.00 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax · last filed 2025-02-25
- Elanco Animal Health Incorporated other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, tax for fiscal 2024 was $4.00M, a 33.33% increase from fiscal 2023.
- Elanco Animal Health Incorporated other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, tax for fiscal 2023 was $3.00M, a 72.73% decline from fiscal 2022.
- Elanco Animal Health Incorporated other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, tax for fiscal 2022 was $11.00M.
- Elanco Animal Health Incorporated other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, tax for fiscal 2021 was $0.00.
| Period end | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax 12 month |
|---|---|
| 2024-12-31 | $4.00M 10-K · filed 2025-02-25 |
| 2023-12-31 | $3.00M 10-K · filed 2025-02-25 |
| 2022-12-31 | $11.00M 10-K · filed 2025-02-25 |
| 2021-12-31 | $0.00 10-K · filed 2024-02-26 |
| 2020-12-31 | $0.00 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |